Head & neck · 2026
History of Head and Neck Cancer as a Predictor of Recurrence and Second Primary Tumors After Transoral Videolaryngoscopic Surgery in Patients With Hypopharyngeal Squamous Cell Carcinoma.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Katoh Mitsuhiko, Eguchi Kohtaro, Ito Tatsuya, Tanaka Akihisa, Watanabe Takane, Hayashi Takaaki, Sakai Azusa, Sakai Toshihiko, Takahashi Hideaki, Honma Yoshitaka, Fushimi Chihiro, Omura Go, Yoshimoto Seiichi
Аннотация
BACKGROUND: Surveillance after transoral videolaryngoscopic surgery (TOVS) for early-stage hypopharyngeal squamous cell carcinoma (HPSCC) remains unvalidated, particularly regarding posttreatment local recurrence and second primary head and neck squamous cell carcinoma (HNSCC).
METHODS: We retrospectively reviewed 84 patients with early-stage HPSCC treated with TOVS at a single high-volume center. Post-TOVS "HNSCC events" were defined as local recurrence or second primary HNSCC diagnosed after TOVS. Event-free survival (EFS) was defined as time to first post-TOVS HNSCC event or death.
RESULTS: Median follow-up was 49.3 months. Two-year EFS and overall survival (OS) were 49.0% and 93.8%, and 2-year cause-specific survival was 100%. Prior HNSCC before the index HPSCC independently predicted worse EFS (HR 4.3, 95% CI 2.3-8.0; p < 0.0001): 2-year EFS was 73.8% without versus 23.0% with prior HNSCC, while OS and cause-specific survival were comparable.
CONCLUSIONS: Prior HNSCC is the dominant predictor of post-TOVS EFS, supporting risk-adapted surveillance.
METHODS: We retrospectively reviewed 84 patients with early-stage HPSCC treated with TOVS at a single high-volume center. Post-TOVS "HNSCC events" were defined as local recurrence or second primary HNSCC diagnosed after TOVS. Event-free survival (EFS) was defined as time to first post-TOVS HNSCC event or death.
RESULTS: Median follow-up was 49.3 months. Two-year EFS and overall survival (OS) were 49.0% and 93.8%, and 2-year cause-specific survival was 100%. Prior HNSCC before the index HPSCC independently predicted worse EFS (HR 4.3, 95% CI 2.3-8.0; p < 0.0001): 2-year EFS was 73.8% without versus 23.0% with prior HNSCC, while OS and cause-specific survival were comparable.
CONCLUSIONS: Prior HNSCC is the dominant predictor of post-TOVS EFS, supporting risk-adapted surveillance.